High admission glucose levels predict worse short-term clinical outcome in non-diabetic patients with acute myocardial infraction: a retrospective observational study

摘要

Patients with acute myocardial infarction (AMI) often accompanied by admission hyperglycemia, which usually predicts a poor clinical outcomes for non-diabetes mellitus. Appropriate cut-point to identify high risk individuals in these patients remains controversial. One thousand six hundred ninety-eight non-diabetes AMI patients in this retrospective study were divided into 3 groups according to admission glucose levels (euglycemia group≤140?mg/dL, moderate hyperglycemia group 141–179?mg/dL, severe hyperglycemia group≥180?mg/dL). The primary endpoint of this study was all-cause in-hospital mortality rate. In-hospital motality related risk factors was analyzed by multivariate binary logistic regression analyses. All myocardial necrosis markers and Log NT-proBNP in severe hyperglycemia group were significantly higher than those in the other 2 groups. Logistic regression showed that independent predictors of the in-hospital mortality rate in non-diabetic patients with AMI were age (OR?=?1.057, 95% CI 1.024–1.091, P??0.001), logarithm of the N-terminal pro-brain natriuretic peptide (OR?=?7.697, 95% CI 3.810–15.550, P??0.001), insufficient myocardial reperfusion (OR?=?7.654, 95% CI 2.109–27.779, P??0.001), percutaneous coronary intervention (OR?=?0.221, 95% CI 0.108–0.452, P??0.001) and admission glucose (as categorical variable). Patients with moderate hyperglycemia (OR?=?1.186, 95% CI 0.585–2.408, P?=?.636) and severe hyperglycemia (OR?=?4.595, 95% CI 1.942–10.873, P?=?0.001) had a higher all-cause in-hospital mortality rate compared with those with euglycemia after AMI in non-diabetic patients. The all-cause in-hospital mortality risk increases remarkably as admission glucose levels elevated in non-diabetic patients with AMI, especially in patients with admission glucose levels ≥180?mg/dL. Severe admission hyperglycemia could be regarded as prospective high-risk marker for non-diabetic AMI patients.